Riskpilot← Back to searchSign inGet full accessVetrepharm ApS
APSDissolvedCVR 15206802Præstelunden 3Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19911 employees
Revenue 2019
DKK -40K
-67% vs 2018
EBITDA margin
179.9%
+61% vs 2018
Equity ratio
-23.2%
Financial strength
Net profit 2019
DKK -84K
+58% vs 2018
| Revenue | DKK -40K | -67% |
| EBITDA | DKK -71K | +61% |
| Net profit | DKK -84K | +58% |
| Total assets | DKK 63K | -94% |
| Equity | DKK -15K | -102% |
| Employees | 1 | — |
Legal name
Vetrepharm ApS
CVR number
15206802
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. juni 1991
Share capital
DKK 50.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Præstelunden 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.030 | 1.070 | 1.073 | 678 | 50 | 129 | -120 | -40 |
| Staff expenses | -613 | -431 | -380 | -413 | -85 | -74 | -63 | -32 |
| EBITDA | 418 | 640 | 693 | 265 | -35 | 55 | -183 | -71 |
| Depreciation & amort. | 54 | -49 | -46 | -15 | -6 | -8 | -3 | -17 |
| EBIT | 363 | 591 | 648 | 249 | -40 | 46 | -186 | -88 |
| Net financials | 24 | 32 | 31 | 17 | 9 | 8 | 9 | 4 |
| Profit before tax | 387 | 623 | 679 | 266 | -32 | 54 | -177 | -84 |
| Tax | 98 | 157 | 169 | 66 | -6 | 13 | 23 | -0 |
| Net profit | 289 | 466 | 510 | 200 | -26 | 42 | -200 | -84 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 1.866 | 2.257 | 2.235 | 2.028 | 1.161 | 1.317 | 1.049 | 63 |
| Equity | 1.377 | 1.393 | 1.403 | 1.603 | 1.078 | 1.119 | 919 | -15 |
| Long-term debt | 0 | 0 | 25 | 25 | 0 | 0 | 0 | 0 |
| Short-term debt | 488 | 864 | 832 | 425 | 83 | 197 | 130 | 78 |
| Total debt | 488 | 864 | 832 | 425 | 83 | 197 | 130 | 78 |
EBITDA margin
-7133200.0%
This company
15.8%
Market median
-45146935% vs market
20122019
Equity ratio
-23.2%
This company
38.2%
Market median
-161% vs market
20122019
Return on equity
-8412100.0%
This company
18.4%
Market median
-45718035% vs market
20122019
Net profit margin
-8412100.0%
This company
8.1%
Market median
-103853186% vs market
20122019
Asset turnover
-0.63×
This company
1.12×
Market median
-156% vs market
20122019
Debt / equity
5.30×
This company
0.62×
Market median
-755% vs market
20122019
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Audit | 1991 | — | — | |
ET | Audit | 1991 | — | — |
KJ Management | Management | 1991 | — | — |
IK Management | Management | 1991 | — | — |
PE Management | Management | 1991 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1991 | — | — | |
| Board of Directors | 2009 | — | — | |
| Board of Directors | 2003 | — | — | |
| Board of Directors | 1991 | — | — | |
| Board of Directors | 1991 | — | — | |
| Board of Directors | 2003 | — | — | |
| Board of Directors | 1991 | — | — | |
| Chairman | 2003 | — | — | |
| Board of Directors | 2002 | — | — | |
| Chairman | 2009 | — | — | |
| Board of Directors | 1991 | — | — | |
| Chairman | 1991 | — | — | |
| Board of Directors | 1999 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
KB HOLDING, BRANDE ApS | Company | 100.0% | 100.0% | 2009 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Vetrepharm ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| SR, STATSAUTORISERET REVISIONSAKTIESELSKAB | Audit | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Kristian Johannes Borum | Management | 0 companies |
| Ingerlise Kofod | Management | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Ulf Svejgaard Poulsen | Board of Directors | 0 companies |
| Ninna Bork Christensen | Board of Directors | 0 companies |
| Nina Boelsgaard Kieffer | Board of Directors | 0 companies |
| Michael Keith Thompson | Board of Directors | 0 companies |
| Kurt Langbo | Board of Directors | 0 companies |
| Poul Michael Bjørnskov | Board of Directors | 0 companies |
| Fiona Anne Fox | Board of Directors | 0 companies |
| Ulf Bjerre | Chairman | 0 companies |
| Hugh Alasdair Fell | Board of Directors | 0 companies |
| Klaus Bork Hansen | Chairman | 0 companies |
| Eli Rubech Rasmussen | Board of Directors | 0 companies |
| Susanne Saul Stakemann | Chairman | 0 companies |
| Mariane Kirstine Kempel | Board of Directors | 0 companies |